1. Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy
- Author
-
T. Kuan Yu, Amit Kumar Garg, Welela Tereffe, George H. Perkins, Eugene Huang, Wendy A. Woodward, Julia L. Oh, Funda Meric-Bernstam, Thomas A. Buchholz, Karin Hahn, Mary Jane Oswald, and Eric A. Strom
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Breast Neoplasms ,Article ,Breast cancer ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Risk factor ,Mastectomy ,Neoadjuvant therapy ,Survival analysis ,Neoplasm Staging ,Retrospective Studies ,Chemotherapy ,Radiation ,business.industry ,Age Factors ,Retrospective cohort study ,medicine.disease ,Survival Analysis ,Neoadjuvant Therapy ,Radiation therapy ,Chemotherapy, Adjuvant ,Doxorubicin ,Lymphatic Metastasis ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Postmastectomy radiotherapy (PMRT) improves locoregional control (LRC) in patients with high-risk features after mastectomy. Young age continues to evolve as a potentially important risk factor. The objective of this study was to assess the benefits of PMRT in patients35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer.We retrospectively analyzed 107 consecutive breast cancer patients35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT. The treatment groups were compared in terms of LRC and overall survival.Despite more advanced disease stages, the patients who received PMRT (n = 80) had greater rates of LRC (5-year rate, 88% vs. 63%, p = 0.001) and better overall survival (5-year rate, 67% vs. 48%, p = 0.03) than patients who did not receive PMRT (n = 27).Among breast cancer patients35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT. The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy.
- Published
- 2007
- Full Text
- View/download PDF